You just read:

Aesculap Biologics, LLC Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of NOVOCART® 3D in Patients with Articular Cartilage Defects of the Knee

News provided by

Aesculap, Inc.

Feb 28, 2019, 13:41 ET